Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1335355 | 0.98 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL799678 | 0.89 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5353245 | 0.89 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3270220 | 0.87 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891470 | 0.87 | MEN1 (0.73) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5353252 | 0.87 | MEN1 (0.68) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3739 | 0.87 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.86 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.86 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.86 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4324836-A1 | NOVEL BORON CARRIER, PREPARATION METHOD AND PHARMACEUTICAL FORMULATION THEREOF | Peking University (CN) | 2024-02-21 | — | — | EP | claimed |
| CN-115260107-B | Antitumor prodrug, pharmaceutical composition and application thereof in tumor targeted therapy field | 烟台邦杰生物科技有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-115581780-A | Nuclide medicine integrating diagnosis and treatment, application, medicinal preparation and preparation method thereof | 北京大学深圳研究生院 | 2023-01-10 | — | — | CN | claimed |
| EP-3331959-B1 | ANIONIC CURABLE COMPOSITIONS | DESIGNER MOLECULES INC (US) | 2022-10-05 | — | — | EP | claimed |
| US-20220204696-A1 | PHENOLIC FUNCTIONALIZED POLYIMIDES AND COMPOSITIONS THEREOF | DESIGNER MOLECULES, INC | 2022-06-30 | — | — | US | claimed |
| CN-112979686-B | Novel boron carrier, preparation method and pharmaceutical preparation thereof | 北京大学 | 2022-04-08 | — | — | CN | claimed |
| CN-111233871-B | Preparation method of temozolomide | 江苏美迪克化学品有限公司 | 2021-11-12 | — | — | CN | claimed |
| CN-112979686-A | Novel boron carrier, preparation method and pharmaceutical preparation thereof | 北京大学 | 2021-06-18 | — | — | CN | claimed |
| CN-111233871-A | Preparation method of temozolomide | 江苏美迪克化学品有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | TIAN JIN KINSLY PHARMACEUTICAL R&D CO. LTD. (CN) | 2008-02-21 | — | — | US | claimed |
| EP-1798234-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | Tianjin Tasly Group Co., Ltd. (CN) | 2007-06-20 | — | — | EP | claimed |
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | claimed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | claimed |
| US-20260071103-A1 | Anionic Curable Compositions | DESIGNER MOLECULES INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071104-A1 | Anionic Curable Compositions | DESIGNER MOLECULES INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4408941-A1 | ANTIFOULING COMPOUND, METHOD AND USES THEREOF | Universidade Do Porto (PT) | 2024-08-07 | — | — | EP | disclosed |
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | disclosed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | disclosed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | disclosed |
| EP-0252682-A2 | Tetrazines | MAY & BAKER LIMITED (GB) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TET1, SLC16A1, ADH1A | MEN1 222/4885PABPC1 4434/4885KMT2A 1472/4885 |
| US-20260071104-A1 | Anionic Curable Compositions | VCL, ITGA8, GABRE | MEN1 613/4885PABPC1 2184/4885KMT2A 1659/4885 |
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | MGMT, TET1, CYP2C8 | MEN1 211/4885PABPC1 3682/4885KMT2A 597/4885 |
| US-20260071103-A1 | Anionic Curable Compositions | CDH1, ESD, SETD2 | MEN1 603/4885PABPC1 1450/4885KMT2A 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.